** Drug developer Alpha Cognition ACOG.O rises 12.5% to $5.91
** ACOG says it has launched its oral therapy, Zunveyl, commercially to treat mild to moderate Alzheimer's disease (AD)
** Alzheimer's is a progressive brain disorder that slowly destroys memory, thinking skills, and eventually the ability to do simple tasks, which is the most common form of dementia affecting nearly 7 million people
** Co says patients can now access the drug in 5 milligram (mg), 10 mg and 15 mg doses
** Zunveyl was approved by the FDA to treat AD in July 2024
** Brokerage H.C. Wainwright estimates Zunveyl to generate $540 millon in peak annual sales in the US by the late 2030s
** As of last close, ACOG down ~65% in the past 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。